Cancer Archives

oncimmune liquid biopsy lung cancer test

News and Trends 10 Sep 2019

Blood Test Increases Early Lung Cancer Diagnosis in UK Trial

A blood test for anti-cancer antibodies, developed by the UK diagnostics company Oncimmune, detected more early cases of lung cancer than standard clinical monitoring procedures in a trial with more than 12,000 patients. Oncimmune’s trial recruited 12,209 patients with a high risk of developing lung cancer through smoking and family history, and monitored them for […]

September 10, 2019 - 3 minutesmins - By Jonathan Smith

cancer cell therapy immunotherapy achilles therapeutics

News and Trends 3 Sep 2019

UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost

The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies in humans for the first time. The large Series B round will fund two phase I/IIa clinical trials of Achilles’ preclinical immunotherapy which are expected to start this year: one in non-small cell lung cancer and the other in […]

September 3, 2019 - 2 minutesmins - By Jonathan Smith

dendritic cell immunicum cancer immunotherapy cell therapy

News and Trends 29 Aug 2019

Off-the-Shelf Kidney Cancer Immunotherapy More Than Doubles Recovery in Phase II

An off-the-shelf cancer immunotherapy developed by the Swedish biotech Immunicum has eradicated kidney tumors in 11% of treated patients compared with just 4% of patients given standard treatments in a phase II trial. Immunicum is developing a cell immunotherapy to treat metastatic renal cell carcinoma. This advanced form of kidney cancer is particularly hard to […]

August 29, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 12 Aug 2019

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site have pushed back its CAR-T cell immunotherapy programs. Autolus is developing treatments for blood cancer that involve engineering patients’ own immune cells to kill cancer cells, known as autologous CAR-T cell immunotherapies. Earlier this year, Autolus licensed a new manufacturing […]

August 12, 2019 - 2 minutesmins - By Jonathan Smith

adc therapeutics genomics sophia genetics blood cancer

News and Trends 6 Aug 2019

ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment

Two companies based in Lausanne, Switzerland — ADC Therapeutics and the genomics company SOPHiA Genetics — have signed a deal to identify patients most likely to respond to a blood cancer drug. ADC Therapeutics will send SOPHiA Genetics blood samples collected from an ongoing phase II trial. The trial is testing a treatment for patients […]

August 6, 2019 - 2 minutesmins - By Jonathan Smith

Catherine Pickering iOnctura e1575382680993

Interview 22 Jul 2019

Turning Shelved Drugs into a New Promise for Immuno-Oncology

After working for 12 years at Merck, Catherine Pickering decided to take a risk and create iOnctura, a spin-out company exploring a new application in immuno-oncology for a drug candidate that had been shelved. In the last decade, there has been a massive boom in the development of cancer therapies that use and enhance the […]

July 22, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

captor therapeutics cancer treatment protein degradation wroclaw

Startup Scout 19 Jul 2019

This Biotech Breaks Down ‘Undruggable’ Proteins to Treat Cancer

In the Polish city of Wrocław, Captor Therapeutics is developing cancer treatments that destroy disease-causing proteins. Mission: To develop cancer treatments able to degrade proteins that are normally outside the reach of traditional drugs, called the ‘undruggable proteome’. Small molecule drugs are able to target a small minority of proteins in the cell, such as […]

July 19, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 18 Jul 2019

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more. This IPO is one of the biggest in biotech history, behind the whopping €530M Nasdaq entry from US mRNA biotech Moderna last year. It’s also to […]

July 18, 2019 - 2 minutesmins - By Jonathan Smith

omics aromics barcelona panorama mesothelioma

Startup Scout 12 Jul 2019

This Biotech Uses ‘Omics’ to Develop Treatments for Drug-Resistant Cancer

Next time you travel to Barcelona, Spain, check out Aromics, a biotech that is using genomics and proteomics to develop treatments for cancers such as malignant mesothelioma, which can be caused by asbestos. Mission: To use omics technology to treat drug-resistant cancers, as well as to identify cancer biomarkers that could improve monitoring in clinical […]

July 12, 2019 - 3 minutesmins - By Jonathan Smith

adc therapeutics antibody drug conjugates

News and Trends 9 Jul 2019

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M) Series E round to finance the development of a phase II antibody-drug conjugate treatment for blood cancer. With its big Series E complete, the company is in a good financial position to prepare for the commercialization of its lead candidate […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

biontech cancer vaccine mrna immunotherapy

News and Trends 9 Jul 2019

BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer

In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

evotec dna damage repair parp inhibitor cancer

News and Trends 8 Jul 2019

Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair

Breakpoint Therapeutics, a spinoff from the German biotech Evotec, has raised €30M to develop drugs that block DNA repair mechanisms in drug-resistant cancers. Breakpoint Therapeutics aims to develop first-in-class drugs that kill cancer cells by sabotaging their DNA repair machinery. Having taken on a number of Evotec’s drug development programs, Breakpoint aims to have its […]

July 8, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Blood Test Increases Early Lung Cancer Diagnosis in UK Trial

UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost

Off-the-Shelf Kidney Cancer Immunotherapy More Than Doubles Recovery in Phase II

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment

Turning Shelved Drugs into a New Promise for Immuno-Oncology

This Biotech Breaks Down ‘Undruggable’ Proteins to Treat Cancer

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

This Biotech Uses ‘Omics’ to Develop Treatments for Drug-Resistant Cancer

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer

Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!